Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) shares traded 39.63% higher at $9.09 on Wall Street last session.
In accordance with the data, 3 analysts cover Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $240.00 and a low of $24.00, we find $132.00. Given the previous closing price of $6.51, this indicates a potential upside of 1927.65 percent. QNRX stock price is now 52.57% away from the 50-day moving average and -31.61% away from the 200-day moving average. The market capitalization of the company currently stands at $8.97M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
It has been rated a hold by 1 analysts and a buy by 2. Brokers who have rated the stock have averaged $132.00 as their price target over the next twelve months.
There have been several recent changes in the stakes of large investors in QNRX stock. A new stake in Quoin Pharmaceuticals Ltd. shares was purchased by VIRTU FINANCIAL LLC during the first quarter worth $112,000. RENAISSANCE TECHNOLOGIES LLC invested $11,000 in shares of QNRX during the first quarter. In the first quarter, UBS GROUP AG acquired a new stake in Quoin Pharmaceuticals Ltd. valued at approximately $5,000.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) opened at $7.29 on Friday. During the past 12 months, Quoin Pharmaceuticals Ltd. has had a low of $5.04 and a high of $337.32. As of last week, the company has a debt-to-equity ratio of 0.38, a current ratio of 4.20, and a quick ratio of 4.20. The fifty day moving average price for QNRX is $6.02 and a two-hundred day moving average price translates $13.20 for the stock.
The latest earnings results from Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$4.08, missing analysts’ expectations of -$3.39 by -0.69. This compares to -$2.51 EPS in the same period last year. The company reported revenue of $2.78 million for the quarter, compared to $2.18 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 27.57 percent.
Quoin Pharmaceuticals Ltd.(QNRX) Company Profile
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; a Master Service Agreement with Therapeutics Inc.; and a research agreement with Queensland University of Technology. The company was founded in 2018 and is based in Ashburn, Virginia.
